Please login to the form below

Not currently logged in
Email:
Password:

J&J’s COVID-19 vaccine generates positive pre-clinical results

Experimental vaccine begins first-in-human trial this month

J&J

An experimental vaccine candidate currently being developed by Johnson and Johnson has proved promising in early, pre-clinical studies.

The vaccine, Ad26.COV2.S, induced a robust immune response in monkeys, demonstrated by high levels of neutralising antibodies. According to J&J, this immune response successfully prevented subsequent infection and provided complete or near-complete protection from the SARS-CoV-2 virus, which causes COVID-19.

In the studies, J&J’s researchers initially immunised the animals with a number of vaccine candidates – out of seven vaccine prototypes tested in the study, scientists found that Ad26.COV2.S elicited the highest levels of neutralising antibodies to SARS-CoV-2.

All six animals that received a single immunisation with the lead vaccine candidate showed no detectable virus in their lower respiratory tract after exposure to SARS-CoV-2, and only one showed very low levels of the virus in a nasal swab at two time points.

Based on the promising results from the animal study, J&J has started a phase 1/2a human clinical trial of the vaccine trial in the US and Belgium. This clinical trial programme will evaluate both one- and two-dose regimens of Ad26.COV2.S in over 1,000 health adults aged 18 to 55 years, as well as adults aged 65 and over.

If all goes to plan in the first-in-human clinical trials, J&J hopes to begin a pivotal phase 3 trial of the single vaccine dose versus placebo in September, as well as a parallel phase 3 study of a two-dose regimen versus placebo.

The company added that it will emphasise representation of populations that have been the most impacted by the pandemic in the phase 3 trial programme. In the US, this would include significant representation of participants over 65 years of age and certain minority ethnic groups.

J&J and the US government’s Biomedical Advanced Research and Development Authority (BARDA) have collectively committed $1bn to the vaccine project, which will be spent on R&D and clinical testing of the vaccine.

“We are excited to see these pre-clinical data because they show our SARS-CoV-2 vaccine candidate generated a strong antibody response and provided protection with a single dose,” said Paul Stoffels, vice chairman of the executive committee and chief scientific officer, J&J.

“The findings give us confidence as we progress our vaccine development and upscale manufacturing in parallel, having initiated a phase 1/2a trial in July with the intention to move into a phase 3 trial in September," he added.

Article by
Lucy Parsons

31st July 2020

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....

Infographics